Health & Medication Blog
Evidence-based guides, comparisons, and practical advice for GLP-1 medications, TRT, HRT, mental health, and more. Updated regularly with the latest research, FDA news, and pricing.
Wegovy HD 7.2mg: Everything You Need to Know About the New High Dose
Novo Nordisk's Wegovy HD brings semaglutide to 7.2mg — tripling the original dose. The STEP UP trial shows it closing the gap with Zepbound on weight loss. Here's the full breakdown.
Using Foundayo for Weight Maintenance After Zepbound: Lilly's Strategy Explained
Eli Lilly did not create Foundayo by accident. The oral GLP-1 pill is the second half of a deliberate two-product strategy: lose aggressively with Zepbound, then maintain conveniently with Foundayo. Here is how the playbook works and whether it makes sense for you.
GLP-1 Medications for PCOS Weight Loss: What the Research Shows
PCOS makes weight loss harder. Here's what the research says about using GLP-1 medications like Foundayo, Ozempic, and Zepbound for PCOS.
Foundayo Weight Loss Timeline: What to Expect Month by Month
Here's exactly what to expect from Foundayo — from your first 0.8mg pill through reaching the maximum dose, month by month.
CagriSema: Everything You Need to Know About Novo Nordisk's Next Weight Loss Drug
CagriSema pairs semaglutide with the amylin analog cagrilintide for 22.7% weight loss in trials — rivaling Zepbound. Here's everything we know ahead of the expected October 2026 FDA decision.
Retatrutide: Lilly's Triple Agonist With 28.7% Weight Loss — What We Know
Retatrutide hit 28.7% weight loss in Phase 2 — the most ever recorded in an obesity trial. Lilly's triple agonist is now in Phase 3, with approval possible by 2027-2028.
GLP-1 Drug Pipeline 2026-2027: Every New Weight Loss Medication Coming Next
At least six major obesity drugs are in Phase 2-3 trials right now. Here's every GLP-1 and incretin medication in the pipeline for 2026 and 2027.
Foundayo Real Results: What Patients Are Reporting in the First Week
Foundayo has been available for just days since its April 6 launch. Here's what early patients are saying so far — and what you should realistically expect in week one.
How to Get Foundayo in 2026: Prescription, Pricing & Where to Buy
Foundayo is FDA-approved and shipping now. Here's exactly how to get it — LillyDirect, Amazon Pharmacy, telehealth, insurance, and every way to save.
Can You Use Foundayo for Type 2 Diabetes? What We Know About Orforglipron and Blood Sugar
Foundayo is FDA-approved for weight loss, not diabetes — yet. But ATTAIN-2 trial data shows a 1.6% A1C reduction. Here is what the science says and when the diabetes approval might come.
Awiqli vs Daily Insulin: Is Once-Weekly Insulin Right for You?
Awiqli is the first once-weekly insulin, offering 52 injections per year instead of 365. But is it as effective as daily Lantus or Tresiba? Here is the complete comparison for type 2 diabetes patients.
What to Eat on Foundayo: Foods That Help (and Hurt) Your Results
Foundayo does not require strict food restrictions, but smart eating boosts results and reduces side effects. Learn which foods help manage nausea, support muscle retention, and enhance weight loss on orforglipron.
Foundayo Dosing Schedule: Complete Titration Guide (0.8mg to 17.2mg)
Master your Foundayo titration with a clear schedule from 0.8mg to 17.2mg. This guide covers dose increases, what to expect at each level, missed dose protocols, drug interactions, and cost per tier.
How to Get Foundayo Prescribed: Doctor Visit, Telehealth & Checklist
Foundayo is now available by prescription for adults with obesity or overweight with weight-related conditions. Discover the three pathways to getting prescribed — from your PCP to telehealth providers — along with a complete appointment checklist and what to say to your doctor.
Wegovy Pill Dosing Schedule: Complete Titration Guide (1.5mg to 25mg)
The oral Wegovy dosing schedule spans four months, starting at 1.5 mg and gradually increasing to the 25 mg maintenance dose. Strict adherence to empty-stomach timing and the SNAC absorption window is essential for maximum efficacy.
CagriSema: Everything We Know About Novo Nordisk's Next-Gen GLP-1 (2026)
CagriSema is Novo Nordisk's fixed-dose combination of cagrilintide (an amylin analog) and semaglutide 2.4 mg in a single weekly injection. With an NDA filed in December 2025, the FDA decision is expected around October 2026.
Planning a medication switch?
Use our free calculator to get a personalized switching plan, dose mapping, and cost comparison.
Try the MedSwitcher CalculatorResearch without missing the move
Get the important GLP-1 updates, not more noise
We’ll send the high-signal stuff only: pricing changes, shortages, and new switch guidance worth acting on.
- Price and access changes
- New medication comparisons
- Actionable switch guidance
No spam. Unsubscribe anytime. We never share your email.